Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker MRNA
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | Stephen Hoge President | MRNA Moderna, Inc. | Sale | 39,145 | $220.72 | $8.6M Sale | Form 4 ↗ |
| Oct 14, 2026 | Stephen Hoge President | MRNA Moderna, Inc. | Sale | 450 | $214.15 | $96.4K Sale | Form 4 ↗ |
| Oct 14, 2026 | Stephen Hoge President | MRNA Moderna, Inc. | Sale | 38,774 | $213.47 | $8.3M Sale | Form 4 ↗ |
| Sep 15, 2026 | Stephen Hoge President | MRNA Moderna, Inc. | Sale | 40,281 | $146.07 | $5.9M Sale | Form 4 ↗ |
| Sep 14, 2026 | Stephen Hoge President | MRNA Moderna, Inc. | Sale | 40,294 | $144.13 | $5.8M Sale | Form 4 ↗ |
| Sep 10, 2026 | James M. Mock Chief Financial Officer | MRNA Moderna, Inc. | Sale | 15,000 | $134.49 | $2.0M Sale | Form 4 ↗ |
| Sep 10, 2026 | James M. Mock Chief Financial Officer | MRNA Moderna, Inc. | Sale | 19,836 | $134.49 | $2.7M Sale | Form 4 ↗ |
| Sep 1, 2026 | Shannon Thyme Klinger Chief Legal Officer | MRNA Moderna, Inc. | Sale | 3,471 | $139.95 | $485.8K Sale | Form 4 ↗ |
| Aug 5, 2026 | Stephane Bancel Chief Executive Officer, Director | MRNA Moderna, Inc. | Sale | 187,044 | $58.79 | $11.0M Sale | Form 4 ↗ |
| Aug 5, 2026 | Stephane Bancel Chief Executive Officer, Director | MRNA Moderna, Inc. | Sale | 39,891 | $58.12 | $2.3M Sale | Form 4 ↗ |
| Aug 5, 2026 | Stephane Bancel Chief Executive Officer, Director | MRNA Moderna, Inc. | Sale | 124,838 | $56.96 | $7.1M Sale | Form 4 ↗ |
| Aug 5, 2026 | Stephane Bancel Chief Executive Officer, Director | MRNA Moderna, Inc. | Sale | 147,473 | $56.21 | $8.3M Sale | Form 4 ↗ |
| Jul 15, 2026 | Stephen Hoge President | MRNA Moderna, Inc. | Sale | 53,336 | $67.60 | $3.6M Sale | Form 4 ↗ |
| Jun 15, 2026 | Stephen Hoge President | MRNA Moderna, Inc. | Sale | 53,336 | $51.37 | $2.7M Sale | Form 4 ↗ |
| Jun 4, 2026 | Shannon Thyme Klinger Chief Legal Officer | MRNA Moderna, Inc. | Sale | 3,471 | $50.00 | $173.6K Sale | Form 4 ↗ |
| May 21, 2026 | Noubar Afeyan Director | MRNA Moderna, Inc. | Sale | 9,263 | $46.84 | $433.9K Sale | Form 4 ↗ |
| May 15, 2026 | Stephen Hoge President | MRNA Moderna, Inc. | Sale | 53,336 | $48.40 | $2.6M Sale | Form 4 ↗ |
| May 1, 2026 | Abbas Hussain Director | MRNA Moderna, Inc. | Sale | 5,682 | $46.63 | $265.0K Sale | Form 4 ↗ |
| Mar 2, 2026 | Shannon Thyme Klinger Chief Legal Officer | MRNA Moderna, Inc. | Sale | 13,885 | $52.29 | $726.0K Sale | Form 4 ↗ |
| Feb 23, 2026 | Stephen Hoge President | MRNA Moderna, Inc. | Sale | 160,009 | $48.84 | $7.8M Sale | Form 4 ↗ |
| Dec 11, 2025 | Noubar Afeyan Director | MRNA Moderna, Inc. | Sale | 23,853 | $29.49 | $703.4K Sale | Form 4 ↗ |
| Dec 9, 2025 | Abbas Hussain Director | MRNA Moderna, Inc. | Sale | 504 | $27.60 | $13.9K Sale | Form 4 ↗ |
| Jun 11, 2025 | Abbas Hussain Director | MRNA Moderna, Inc. | Sale | 312 | $28.00 | $8,736 Sale | Form 4 ↗ |
| Mar 3, 2025 | Stephane Bancel Chief Executive Officer, Director | MRNA Moderna, Inc. | Buy | 57,493 | $31.53 | $1.8M Buy | Form 4 ↗ |
| Mar 3, 2025 | Stephane Bancel Chief Executive Officer, Director | MRNA Moderna, Inc. | Buy | 102,821 | $31.04 | $3.2M Buy | Form 4 ↗ |
| Mar 3, 2025 | Paul Sagan Director | MRNA Moderna, Inc. | Buy | 31,620 | $31.76 | $1.0M Buy | Form 4 ↗ |
| Dec 9, 2024 | Shannon Thyme Klinger Chief Legal Officer | MRNA Moderna, Inc. | Sale | 529 | $44.68 | $23.6K Sale | Form 4 ↗ |
| Dec 3, 2024 | Shannon Thyme Klinger Chief Legal Officer | MRNA Moderna, Inc. | Sale | 112 | $43.30 | $4,850 Sale | Form 4 ↗ |
| Dec 3, 2024 | Stephen Hoge President | MRNA Moderna, Inc. | Sale | 314 | $43.30 | $13.6K Sale | Form 4 ↗ |
| Nov 29, 2024 | James M. Mock Chief Financial Officer | MRNA Moderna, Inc. | Sale | 1,420 | $42.79 | $60.8K Sale | Form 4 ↗ |
| Nov 29, 2024 | Shannon Thyme Klinger Chief Legal Officer | MRNA Moderna, Inc. | Sale | 1,418 | $42.79 | $60.7K Sale | Form 4 ↗ |
| Nov 29, 2024 | Stephen Hoge President | MRNA Moderna, Inc. | Sale | 291 | $42.79 | $12.5K Sale | Form 4 ↗ |
| Nov 11, 2024 | Stephen Hoge President | MRNA Moderna, Inc. | Sale | 277 | $46.10 | $12.8K Sale | Form 4 ↗ |
| Oct 7, 2024 | James M. Mock Chief Financial Officer | MRNA Moderna, Inc. | Sale | 715 | $60.12 | $43.0K Sale | Form 4 ↗ |
34 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:42 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances